Login to Your Account

Financings Roundup

Threshold Offering Raises $30M for TH-302 Phase III

By Tom Wall

Monday, March 14, 2011
Threshold Pharmaceuticals Inc. expects to raise about $30 million in a registered direct offering to advance clinical trials for its lead hypoxia-activated prodrug TH-302 including a Phase III trial for soft tissue sarcoma expected to start in mid-2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription